The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
BMI ≥35 kilograms per square meter (kg/m²).
History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months.
Current diagnosis or history of diabetes mellitus.
Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to, tricyclic antidepressants, atypical antipsychotics, mood stabilizers, and phentermine.
Unstable weight defined as self-reported change in body weight exceeding 5% within the 3 months prior to Screening.
Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.
Parallel
Ribupatide
DrugSC Injection
Semaglutide
DrugSC Injection
Placebo
DrugSC Injection
Percent Change From Baseline in Body Weight at Week 76
Percentage of Participants with ≥10%, ≥15%, ≥20% and ≥25% Reduction in Body Weight
Change From Baseline in Waist Circumference
Change From Baseline in Absolute Body Weight
Percentage of Participants with ≥5% Reduction in Body Weight